HAE

SEC source: 0001127602-19-030959 · form4.xml · nonDerivative · entry 1

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,759

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-19-030387 · form4.xml · nonDerivative · entry 4

Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,695

F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.28 to $124.87, inclusive.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-19-030387 · form4.xml · nonDerivative · entry 3

Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,074

F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.23 to $124.22, inclusive.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-19-030387 · form4.xml · nonDerivative · entry 2

Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,304

F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.01 to $122.75, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-19-030385 · form4.xml · nonDerivative · entry 4

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,138

F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.09 to $124.96, inclusive.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-19-030385 · form4.xml · nonDerivative · entry 3

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,947

F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.09 to $124.02, inclusive.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-19-030385 · form4.xml · nonDerivative · entry 2

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,671

F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.02 to $123.00, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-19-030383 · form4.xml · nonDerivative · entry 4

Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,014

F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.22 to $124.97, inclusive.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-19-030383 · form4.xml · nonDerivative · entry 3

Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,462

F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.22 to $124.21, inclusive.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-19-030383 · form4.xml · nonDerivative · entry 2

Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,818

F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.21 to $123.18, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-19-030387 · form4.xml · nonDerivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,604

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain performance share units previously reported in Table I on October 8, 2019. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain performance share units previously reported in Table I on October 8, 2019. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-19-030385 · form4.xml · nonDerivative · entry 1

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,771

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain performance share units previously reported in Table I on October 8, 2019. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain performance share units previously reported in Table I on October 8, 2019. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-19-030383 · form4.xml · nonDerivative · entry 1

Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,718

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain performance share units previously reported in Table I on October 8, 2019. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain performance share units previously reported in Table I on October 8, 2019. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-19-030271 · form4.xml · nonDerivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,899

F1 · kind: Represents shares earned from a performance share unit award granted to the reporting person on March 6, 2017, based on the issuer's total shareholder return relative to that of the companies comprising a blended index of the S&P MidCap 400 and S&P SmallCap 600 for the performance period from October 1, 2016 to September 30, 2019, as certified by the Compensation Committee of the Board of Directors on October 4, 2019.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-19-030269 · form4.xml · nonDerivative · entry 1

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,654

F1 · kind: Represents shares earned from a performance share unit award granted to the reporting person on March 6, 2017, based on the issuer's total shareholder return relative to that of the companies comprising a blended index of the S&P MidCap 400 and S&P SmallCap 600 for the performance period from October 1, 2016 to September 30, 2019, as certified by the Compensation Committee of the Board of Directors on October 4, 2019.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-19-030268 · form4.xml · nonDerivative · entry 1

Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,668

F1 · kind: Represents shares earned from a performance share unit award granted to the reporting person on October 25, 2016, based on the issuer's total shareholder return relative to that of the companies comprising a blended index of the S&P MidCap 400 and S&P SmallCap 600 for the performance period from October 1, 2016 to September 30, 2019, as certified by the Compensation Committee of the Board of Directors on October 4, 2019.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-19-030039 · form4.xml · derivative · entry 7

Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,435

Underlying: Common Stock · 5,718 shares

Expires 2024-06-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan.

F8 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-19-030039 · form4.xml · nonDerivative · entry 6

Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,014

F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.55 to $129.00, inclusive.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-19-030039 · form4.xml · nonDerivative · entry 5

Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,481

F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.31 to $127.99, inclusive.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-19-030039 · form4.xml · nonDerivative · entry 4

Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,129

F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.29 to $127.18, inclusive.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-19-030039 · form4.xml · nonDerivative · entry 3

Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,799

F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.24 to $126.16, inclusive.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-19-030039 · form4.xml · nonDerivative · entry 2

Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,108

F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.21 to $124.98, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (7) to this Form 4.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-19-030039 · form4.xml · nonDerivative · entry 1

Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,178

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-19-028195 · form4.xml · derivative · entry 3

Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,925

Underlying: Common Stock · 1,308 shares

Expires 2025-06-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan.

F3 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-19-028195 · form4.xml · nonDerivative · entry 2

Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,695

F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-19-028195 · form4.xml · nonDerivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,226

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-19-028076 · form4.xml · nonDerivative · entry 1

Llorens Josep · CIK 0001750812 · SVP, Global Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,770

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-19-027768 · form4.xml · derivative · entry 3

Bolorforosh Said · CIK 0001741776 · EVP, Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,498

Underlying: Common Stock · 832 shares

Expires 2025-06-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-19-027768 · form4.xml · nonDerivative · entry 2

Bolorforosh Said · CIK 0001741776 · EVP, Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,316

F1 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-19-027768 · form4.xml · nonDerivative · entry 1

Bolorforosh Said · CIK 0001741776 · EVP, Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,973

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-19-027191 · form4.xml · nonDerivative · entry 1

Simon, Christopher · CIK 0001674993 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 304,572

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain performance share units previously reported in Table I on August 15, 2019. This sale is mandated by the Issuer's election under its 2005 Long-Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-19-026736 · form4.xml · nonDerivative · entry 1

Simon, Christopher · CIK 0001674993 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 355,441

F1 · kind: Represents shares earned from a performance share unit award granted to the reporting person on August 16, 2016, based on the issuer's total shareholder return relative to that of the companies comprising a blended index of the S&P MidCap 400 and S&P SmallCap 600 for the performance period from August 4, 2016 to August 4, 2019, as certified by the Compensation Committee of the Board of Directors on August 14, 2019. The award is subject to the reporting person's continued service through the vesting date of August 16, 2019.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-19-026402 · form4.xml · derivative · entry 3

Goldstein Dan · CIK 0001722327 · VP, Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,428

Underlying: Common Stock · 475 shares

Expires 2025-06-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-19-026402 · form4.xml · nonDerivative · entry 2

Goldstein Dan · CIK 0001722327 · VP, Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,789

F1 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-19-026402 · form4.xml · nonDerivative · entry 1

Goldstein Dan · CIK 0001722327 · VP, Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,264

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-19-026407 · form4.xml · nonDerivative · entry 1

GELBMAN RONALD G · CIK 0001210616 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,384

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.08 to $134.15, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-19-025270 · form4.xml · nonDerivative · entry 1

MEELIA RICHARD J · CIK 0001223633 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,067

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

SEC source: 0001127602-19-025272 · form4.xml · nonDerivative · entry 1

Zane Ellen M · CIK 0001369850 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,457

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

SEC source: 0001127602-19-025271 · form4.xml · nonDerivative · entry 1

Pomeroy Claire · CIK 0001603648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,956

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-19-025269 · form4.xml · nonDerivative · entry 1

KROLL MARK W · CIK 0001259254 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,617

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

SEC source: 0001127602-19-025267 · form4.xml · nonDerivative · entry 1

GELBMAN RONALD G · CIK 0001210616 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,080

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: Balance reflects the reporting person's transfer of 4,442 shares of the Issuer's common stock to his former spouse pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by his former spouse.

SEC source: 0001127602-19-025265 · form4.xml · nonDerivative · entry 1

Dockendorff Charles J · CIK 0001400563 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,340

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

SEC source: 0001127602-19-025263 · form4.xml · nonDerivative · entry 1

BURZIK CATHERINE M · CIK 0001261141 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,755

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

SEC source: 0001127602-19-025262 · form4.xml · nonDerivative · entry 1

ABERNATHY ROBERT E · CIK 0001222888 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,065

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

SEC source: 0001127602-19-023747 · form4.xml · nonDerivative · entry 1

Simon, Christopher · CIK 0001674993 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 241,143

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0000899243-19-017286 · doc4.xml · derivative · entry 5

Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,779

Underlying: Common Stock · 2,890 shares

Expires 2024-06-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan.

F3 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.

SEC source: 0000899243-19-017286 · doc4.xml · nonDerivative · entry 4

Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,918

F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0000899243-19-017286 · doc4.xml · nonDerivative · entry 3

Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,177

F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0000899243-19-017286 · doc4.xml · nonDerivative · entry 2

Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,674

F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0000899243-19-017286 · doc4.xml · nonDerivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,564

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan.

F2 · balance_after: This number includes unvested restricted stock units previously reported.